Research
Hormonal
Reduced Insulin/IGF-1 Signaling (IIS) extends lifespan by allowing transcription factors like DAF-16 and HSF-1 to enter the nucleus and activate proteostasis genes, including chaperones and autophagy components.
Reduced Insulin/IGF-1 Signaling (IIS) extends lifespan by allowing transcription factors like DAF-16 and HSF-1 to enter the nucleus and activate proteostasis genes, including chaperones and autophagy components.
GoodSupportsHIGH confidence
Reduced IIS activity extends lifespan in both invertebrate and vertebrate species... reduced IIS activity allows it [DAF-16] to enter the nucleus, activating a diverse transcriptional profile that promotes extended lifespan.
Why this rating
Well-characterized in C. elegans and other species; genetic evidence is strong.
Source
Aging as an Event of Proteostasis Collapse
Rebecca C. Taylor et al. · Cold Spring Harbor Perspectives in Biology · 2011
DOI 10.1101/cshperspect.a004440
narrative_reviewCited 549×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Reduction of dietary intake (Dietary Restriction) extends lifespan by modulating the proteostasis machinery, specifically by reducing translation rates and enhancing autophagy, thereby preventing the accumulation of misfolded proteins.Good
- Autophagy induction, particularly macroautophagy, is necessary for lifespan extension by Dietary Restriction and reduced IIS, and pharmacological induction (e.g., rapamycin) can increase longevity.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →